(28 days)
The endoscope is a sterile, single endoscope intended for endoscopic procedures and examination within the nasal lumens and upper airway anatomy. The endoscope is intended to provide visualization via a monitor.
The endoscope is intended for use in a hospital environment. It is designed for use in adults.
The Ambu® aScope™ 4 RhinoLaryngo Slim is a sterile single use flexible endoscope for examination of the nasal lumens and upper airway anatomy.
Ambu® aScope™ 4 RhinoLaryngo Slim has the following physical and performance characteristics:
Maneuverable tip controlled by the user Flexible insertion cord Camera and LED light source at the distal tip Sterilized by Ethylene Oxide For single use
This document is a 510(k) Summary for the Ambu aScope 4 RhinoLaryngo Slim, indicating that it is a sterile, single-use, flexible endoscope for examination of the nasal lumens and upper airway anatomy. It provides an overview of the device's characteristics and a comparison to predicate devices to establish substantial equivalence.
Here's an analysis of the acceptance criteria and study information:
1. Table of Acceptance Criteria and Reported Device Performance
The acceptance criteria are generally established by compliance with recognized consensus standards and performance tests. The device performance is reported as meeting these standards.
| Acceptance Criteria (Test Category) | Specific Standard/Test | Reported Device Performance |
|---|---|---|
| Product Specific Standards | ISO 8600-1 | All tests were passed. |
| ISO 8600-3 | All tests were passed. | |
| ISO 8600-4 | All tests were passed. | |
| ISO 594-1 | All tests were passed. | |
| Performance Tests | Length and diameters of insertion cord | All tests were passed. |
| Bending angle, endurance and radius | All tests were passed. | |
| Image Sharpness | All tests were passed. | |
| Shelf Life and Sterile Barrier | ASTM F1980 (Accelerated Aging) | All tests were passed. |
| ASTM D4169 (Shipping Containers) | All tests were passed. | |
| ASTM F1886/F1886M (Seal Integrity - Visual) | All tests were passed. | |
| ASTM F2096 (Gross Leaks - Bubble Test) | All tests were passed. | |
| EN 868-5 (Seal Strength) | All tests were passed. | |
| ASTM F88 (Seal Strength) | All tests were passed. | |
| Electromagnetic Compatibility | IEC 60601-1-2 | All tests were passed. |
| Electrical Safety | IEC 60601-1 | All tests were passed. |
| IEC 60601-2-18 | All tests were passed. | |
| Biocompatibility | ISO10993 (cytotoxicity, irritation, sensitization) | Compliant |
2. Sample Size Used for the Test Set and Data Provenance
The document does not specify a "test set" in the context of clinical data or human subject studies. The data provenance described is primarily bench testing data for device performance, compliance with standards, and material properties. There is no information about country of origin for any human subject data, nor whether it was retrospective or prospective, as no such data is presented.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications
Not applicable. The ground truth for this submission is established through bench testing and compliance with recognized industry standards. There is no mention of expert consensus based on human clinical data for a "test set."
4. Adjudication Method for the Test Set
Not applicable. As described above, there is no "test set" in the context of clinical data requiring an adjudication method.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
No, an MRMC comparative effectiveness study was not done. The document explicitly states "Not applicable" under the "Performance Data - Clinical" section, indicating no clinical studies were performed. This submission relies on substantial equivalence based on technological characteristics and bench testing compared to predicate devices.
6. Standalone (Algorithm Only Without Human-in-the-Loop Performance) Study
Not applicable. This device is an endoscope, a physical medical instrument, not a software algorithm that would have standalone performance in the absence of a human operator. The device's performance is intrinsically linked to its physical properties and intended use by a clinician.
7. Type of Ground Truth Used
The ground truth used for demonstrating compliance and performance is based on engineering specifications, compliance with international and national standards (e.g., ISO, ASTM, IEC), and results from bench testing. For example, the measurement of bending angles, image sharpness, and seal integrity tests against predefined limits or standards constitute the ground truth.
8. Sample Size for the Training Set
Not applicable. This is not a machine learning or AI-based device that requires a "training set." The device is a physical medical instrument.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as there is no training set mentioned or implied for this device.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food & Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo in blue. Underneath the FDA logo is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
May 22, 2019
Ambu A/S % Sanjay Parikh Director, QA/RA Ambu Inc. 6230 Old Dobbin Lane, Suite 250 Columbia, Maryland 21045
Re: K191080
Trade/Device Name: Ambu aScope 4 RhinoLaryngo Slim Regulation Number: 21 CFR 874.4760 Regulation Name: Nasopharyngoscope (flexible or rigid) and accessories Regulatory Class: Class II Product Code: EOB Dated: April 23, 2019 Received: April 24, 2019
Dear Sanjay Parikh:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{1}------------------------------------------------
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
for Michael Ryan Director DHT1C: Division of ENT, Sleep Disordered Breathing, Respiratory and Anesthesia Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Ouality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K191080
Device Name Ambu aScope 4 RhinoLaryngo Slim
Indications for Use (Describe)
The endoscope is a sterile, single endoscope intended for endoscopic procedures and examination within the nasal lumens and upper airway anatomy. The endoscope is intended to provide visualization via a monitor.
The endoscope is intended for use in a hospital environment. It is designed for use in adults.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) | |
|---|---|
| Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
510(k) Summary
This Special 510(k) summary has been prepared in accordance with 21 CFR 807.87(h) and the content and format of the 510(k) summery has been prepared in accordance with 21 CFR 807.92.
| Submitter | Ambu A/SBaltorpbakken 13DK-2750 BallerupDenmarkTel.: +45 7225 2000Fax.: +45 7225 2050 | |||
|---|---|---|---|---|
| Contact Person | Name: Gurpreet Kaur RehalJob Title: Regulatory Affairs ProfessionalAddress: Ambu A/S, Baltorpbakken 13, DK-2750 BallerupTelephone number: +45 7225 2116Fax number: +45 7225 2050 | |||
| Date SummaryPrepared | April 19, 2019 | |||
| Device TradeName | Ambu® aScope™ 4 RhinoLaryngo Slim | |||
| Device CommonName | Rhino-Laryngoscope | |||
| DeviceClassification | Nasopharyngoscopes (Flexible or Rigid)Product Codes: EOB21 CFR 874.4760Class II | |||
| LegallyMarketed | Manufacturer | Trade Name | 510knumber | |
| devices to whichthe device issubstantially | PredicateC: | Ambu A/S | Ambu® aScope™ RLSSlim | K18128 |
| equivalent | Reference:A: | OlympusMedicalSystemsCorporation | Olympus ENF-GP | K01186 |
| ReferenceB: | Ambu A/S | Ambu® aScope™ 4Broncho Slim | K17372 |
{4}------------------------------------------------
| Description ofthe Device | The Ambu® aScope™ 4 RhinoLaryngo Slim is a sterile single use flexibleendoscope for examination of the nasal lumens and upper airwayanatomy. | ||
|---|---|---|---|
| Ambu® aScope™ 4 RhinoLaryngo Slim has the following physical andperformance characteristics:Maneuverable tip controlled by the user Flexible insertion cord Camera and LED light source at the distal tip Sterilized by Ethylene Oxide For single use | |||
| Indications forUse | The endoscope is a sterile, single-use, flexible endoscope intended forendoscopic procedures and examination within the nasal lumens andupper airway anatomy. The endoscope is intended to providevisualization via a monitor.The endoscope is intended for use in a hospital environment. It isdesigned for use in adults. | ||
| Summary of thetechnologicalcharacteristicsin comparison tothe predicatedevices | Specification | Ambu® aScope™RLS Slim | Ambu® aScope™ 4RhinoLaryngo Slim |
| Distal end diameter | 4.2 mm (0.16") | 3.5 mm (0.14") | |
| Insertion corddiameter | 3.8 mm (0.15") | 3.0 mm (0.12") | |
| Working length | 600 mm (23.6") | 300 mm (11.8") | |
| Bending section | 180° up, 180° down | 130° up, 130° down | |
| Max diameter ofinsertion portion | 4.3 mm (0.17") | 3.5 mm (0.14") | |
| Ambu® aScope™ 4 RhinoLaryngo Slim is similar to the predicate device Cand reference A and B devices in the following areas:They are all flexible endoscopes with a maneuverable tip. They all have a handle with a control lever giving the operatorability to steer the tip of the scope up and down. They all provide illumination from the distal tip. They all have the same "field of view" and "direction of view" They all have insertion cord diameters within the same range. The Ambu® aScope™ 4 RhinoLaryngo Slim diameter is similar to thepredicate and reference device:Predicate C has a larger diameter. Reference A has the same working length. Predicate Cand reference B have a longer working length Predicate C and Reference A have same intended use. Predicate C and reference B are single-use device, which aredelivered sterile |
{5}------------------------------------------------
. They are all portable endoscopes. Validation from non-clinical testing demonstrated that these technological features do not raise any new issues of safety and effectiveness of the applicant device. Overall, the line extension scope is narrower in diameter and shorter in length than the predicate device. Furthermore, the following non-dimensional changes are made: . The color of the control lever and tube connection has been changed from gray to purple, to indicate the product variant. The control lever and tube connector are components on the handle and do not have direct or indirect contact with the patient and do not raise new questions of safety and effectiveness. ● The type of Tyvek primary packaging material has been changed to Tyvek 2FS with EP 1250 film. Packaging integrity testing and sterilization validation report have been updated and do not raise new questions of safety and effectiveness. . Adhesive used for water tightness of the camera is changed. Tests that documents compliance with design requirements are performed, including verification using ISO10993 tests for cytotoxicity, irritation and sensitization, and do not raise new questions of safety and effectiveness. Ambu® aScope™ 4 RhinoLaryngo Slim has been successfully tested for its Performance functions, performance and safety as per FDA recognized consensus Data -Bench standards. The following bench data are described for the product line extension in the premarket notification: Declaration of Conformity with the following product specific standards ISO 8600-1, ISO 8600-3, ISO 8600-4 and ISO 594-1 ● Result: All tests were passed. Performance test has been conducted to document the following properties of Ambu® aScope™ 4 RhinoLaryngo Slim: ● Length and diameters of insertion cord ● Bending angle, endurance and radius . Image Sharpness Result: All tests were passed. Performance test has been conducted to document the shelf life and sterile barrier of Ambu® aScope™ 4 RhinoLaryngo Slim, where the aging and sterile Packaging Integrity testing is carried out in accordance with: ● ASTM F1980: Standard Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices ● ASTM D4169: Standard Practice for Performance Testing of Shipping Containers and Systems
{6}------------------------------------------------
| PerformanceData - Clinical | ASTM F1886/F1886M: Standard Test Method for Determining Integrity of Seals for Flexible Packaging by Visual Inspection ASTM F2096: Standard Test Method for Detecting Gross Leaks in Packaging by Internal Pressurization (Bubble Test) (Test Method B - Procedure for Porous Packaging.) Seal Strength tests performed based on: EN 868-5: Packaging for terminally sterilized medical devices – Part 5: Sealable pouches and reels of porous materials and plastic film construction - Requirements and test methods and ASTM F88: Standard Test Method for Seal Strength of Flexible Barrier Materials Test reports that verify the Electromagnetic Compatibility and Electricial Safety: Electromagnetic Compatibility in compliance with IEC 60601-1-2. Electrical Safety in compliance with IEC 60601-1 and IEC 60601-2-18. Result: All tests were passed.Similar requirements and test methods are used in the bench test for the predicate device, which supports the determination of substantial equivalence.The line extension Ambu® aScope™ 4 RhinoLaryngo Slim and predicate device have the same intended use fundamental technology and there are no significant differences that raise different questions of safety and effectiveness.Not applicable. |
|---|---|
| Conclusion | Based on the indication for use, technological characteristics, performance data and comparison to predicate and reference devices it has been concluded that the functionality and intended use of Ambu® aScope™ 4 RhinoLaryngo Slim is substantially equivalent to the predicate device.It is concluded that Ambu® aScope™ 4 RhinoLaryngo Slim is as safe and as effective and perform as well as the predicate device. |
§ 874.4760 Nasopharyngoscope (flexible or rigid) and accessories.
(a)
Identification. A nasopharyngoscope (flexible or rigid) and accessories is a tubular endoscopic device with any of a group of accessory devices which attach to the nasopharyngoscope and is intended to examine or treat the nasal cavity and nasal pharynx. It is typically used with a fiberoptic light source and carrier to provide illumination. The device is made of materials such as stainless steel and flexible plastic. This generic type of device includes the antroscope, nasopharyngolaryngoscope, nasosinuscope, nasoscope, postrhinoscope, rhinoscope, salpingoscope, flexible foreign body claw, flexible biopsy forceps, rigid biopsy curette, flexible biospy brush, rigid biopsy forceps and flexible biopsy curette, but excludes the fiberoptic light source and carrier.(b)
Classification. Class II.